Arbutus Biopharma Corporation ABUS
3.66 USD -0.02 (-0.41%)
At closeNov 6, 2026, 4:50 PM EST
3.65 0.00 -0.14%
After hours · Nov 6, 4:50 PM ET
3.63 Day range 3.75
3.66 52-week range 5.22
- YTD
- -24.01%
- 1 year
- -17.68%
News
benzinga.com FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.
benzinga.com Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that the Company was notified by the